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Abstract
Colorectal cancer (CRC) is a major cause of cancer mortality. Whereas some patients respond well
to therapy, others do not, and thus more precise, individualized treatment strategies are needed. To
that end, we analyzed gene expression profiles from 1,290 CRC tumors using consensus-based
unsupervised clustering. The resultant clusters were then associated with therapeutic response data
to the epidermal growth factor receptor–targeted drug cetuximab in 80 patients. The results of
these studies define six clinically relevant CRC subtypes. Each subtype shares similarities to
distinct cell types within the normal colon crypt and shows differing degrees of ‘stemness’ and
Wnt signaling. Subtype-specific gene signatures are proposed to identify these subtypes. Three
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subtypes have markedly better disease-free survival (DFS) after surgical resection, suggesting
these patients might be spared from the adverse effects of chemotherapy when they have localized
disease. One of these three subtypes, identified by filamin A expression, does not respond to
cetuximab but may respond to cMET receptor tyrosine kinase inhibitors in the metastatic setting.
Two other subtypes, with poor and intermediate DFS, associate with improved response to the
chemotherapy regimen FOLFIRI1 in adjuvant or metastatic settings. Development of clinically
deployable assays for these subtypes and of subtype-specific therapies may contribute to more
effective management of this challenging disease.
Previous studies have identified molecular subtypes of various human cancers by gene
expression profiling2–8, including CRC subtypes9,10. However, these subtypes have not been
associated with outcomes in patients treated with specific therapeutic interventions.
Therefore, we sought to refine the approach of molecular classification of CRC by
associating gene expression profiles of CRC tumors with corresponding clinical response to
cetuximab. We first used consensus-based non-negative matrix factorization (NMF)11 to
cluster two published gene expression data sets (GSE13294 (ref. 12) and GSE14333 (ref.
13)) derived from resected primary CRCs (core data sets, n = 445). These data were
corrected for batch effects and merged using the distance-weighted discrimination
method5,14 before clustering. This analysis defined five distinct high-consensus molecular
subtypes of CRC (Supplementary Fig. 1a–e and Supplementary Results and Discussion).
We used silhouette width2,15 to identify samples that most closely represent one of these
five molecular subtypes, and this analysis yielded a ‘core’ set of 387 CRC tumors
(Supplementary Results and Discussion and Supplementary Fig. 1f). We identified
markers associated with the five subtypes using significance analysis of microarrays
(SAM16, false discovery rate (FDR) = 0), followed by prediction analysis for microarrays
(PAM17, nearest shrunken centroids–based method) to identify 786 subtype-specific
signature genes (a collection dubbed CRCassigner-786; Fig. 1a, Supplementary Results and
Discussion, Supplementary Data and Supplementary Table 1b) with the lowest prediction
error.
We named the five subtypes by the genes preferentially expressed in each (Fig. 1a,b and
Supplementary Fig. 2): (i) goblet-like, defined by high mRNA expression of goblet-specific
MUC2 and TFF3 (ref. 18); (ii) enterocyte, defined by high expression of enterocyte-specific
genes18; (iii) stem-like, with high expression of Wnt signaling targets plus stem cell,
myoepithelial and mesenchymal genes and low expression of differentiation markers; (iv)
inflammatory, marked by comparatively high expression of chemokines and interferon-
related genes; and (v) transit-amplifying, a heterogeneous collection of samples with
variable expression of stem cell and Wnt-target genes. We then condensed the 786-gene
signature into two smaller sub-signatures. One, dubbed as CRCassigner-30, has 30 genes
with high PAM scores and characteristics of specific subtypes that might be used clinically
for robust definition of these subtypes (Fig. 1b and Supplementary Table 1b). The second
comprises a reduced feature set of seven genes (CRCassigner-7) that we explored for
possible development as a classification assay using either quantitative RT-PCR (qRT-PCR)
or immunohistochemistry. Six of these seven markers could be used to classify 50% of 72
patient-derived tumors (10 out of 19 samples using qRT-PCR and 26 out of 53 samples
using immunohistochemistry) into one of the five CRC subtypes (Fig. 1c, Supplementary
Fig. 2g, Supplementary Table 1c,d and Supplementary Methods). The use of the seventh
CRCassigner-7 gene is discussed below and in the Supplementary Results and Discussion.
The inflammatory subtype currently cannot be defined using an immunohistochemistry
assay owing to the lack of antibodies that identify the markers for this subtype. Development
of a clinically deployable qRT-PCR assay will require identification of reference genes and
precisely defined decision thresholds.
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We further validated the colon cancer subtypes in seven independent patient gene expression
profile data sets (n = 744), including a recent The Cancer Genome Atlas study9, by
projecting the CRCassigner-786 genes onto the data sets and then performing NMF
consensus clustering (Supplementary Fig. 3, Supplementary Table 2 and Supplementary
Results and Discussion). Four of our five subtypes were also represented in a panel of
human CRC cell lines19,20 (n = 51; see Supplementary Results and Discussion for
identification of subtypes in cell lines, Fig. 1d, Supplementary Fig. 4a–c and Supplementary
Table 2c). In three cases, we showed that the subtype signature was stably maintained when
subtyped CRC lines were grown as xenograft tumors in mice and analyzed for marker
expression by qRT-PCR (Supplementary Fig. 4d,e).
We next examined the association of CRC subtypes with DFS after surgery for 197 patients
in one of the core CRC data sets, GSE14333 (ref. 13), for which reported follow-up data
were available. We first evaluated DFS for all the samples irrespective of stage or treatment
(adjuvant chemotherapy or chemoradiotherapy21). This did not reveal a significant
association between subtype and DFS (P = 0.12; log-rank test; Supplementary Results and
Discussion, Supplementary Fig. 5b and Supplementary Table 3). We did, however, detect
significant associations of subtypes with DFS within treatment subgroups. In untreated
patients, stem-like–subtype tumors had the shortest DFS, inflammatory and enterocyte
subtypes had intermediate DFS, and transit-amplifying and goblet-like subtypes showed a
good prognosis (P = 0.0003; n = 120; log-rank test, Fig. 1e). However, there was no
significant association between subtype and DFS in the treated patients (n = 77,
Supplementary Fig. 5c). There was a trend suggesting that adjuvant chemotherapy or
chemo-radiotherapy preferentially improved DFS in patients with stem-like–subtype tumors,
whereas both treatments were associated with a detrimental effect in the transit-amplifying
and goblet-like subtypes (Supplementary Fig. 5a–h). These results suggest that stem-like
tumors might be preferentially responsive to adjuvant chemotherapy or chemoradiotherapy,
whereas transit-amplifying– and goblet-like–subtype tumors might not benefit from these
treatments. As there were only 43 events of tumor recurrence among the treated and
untreated samples, additional studies involving larger patient data sets will be needed to test
the validity of the suggested relationships between subtype, treatment and DFS.
We next compared our subtypes with the well-established micro-satellite stability (MSS) or
instability (MSI) phenotypes using GSE13294 (n = 155)12. We observed that 94% (n = 36)
of the inflammatory-subtype samples showed MSI, whereas 86% (n = 42) of the transit-
amplifying and 67% (n = 21) of the stem-like subtypes were MSS (Fig. 1f). We obtained
consistent results by associating MSI status for tumors previously classified with our
subtype signature and querying their core data sets for MSI status using a published MSI
gene signature22 and the nearest template prediction (NTP) algorithm23 (Supplementary Fig.
5i–k). Although there are clear associations between MSI or MSS status and specific
subtypes, the transcriptional signatures and subtype definitions allow refinement beyond
what can be achieved by annotating microsatellite stability status.
The normal colon is composed of cell types with varying degrees of differentiation potential
and specialized functions24. Although colonic stem cells are thought to be the cell of origin
for CRC, more differentiated cells may also be susceptible to transformation18,25,26. We
assigned cell of origin or phenotypes to the transcriptional CRC subtypes defined here using
a published gene signature that discriminates between the normal colon crypt top (where
terminally differentiated cells are transiently located) and the normal crypt base (where stem
cells and their partially differentiated derivatives reside)27. We used the NTP algorithm23
(Supplementary Results and Discussion and Fig. 2a) to show that 98% (n = 44) of the
stem-like subtype tumors were significantly (FDR < 0.2) associated with the crypt base
signature. In addition, we found that several published stem cell–specific gene and pathway
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signatures were significantly associated with the stem-like subtype (Supplementary Fig.
6a,b). In contrast, 92% (n = 52) and 82% (n = 33) of samples from the enterocyte and
goblet-like subtype tumors, respectively, were associated with crypt top by their concordant
gene signatures. The inflammatory subtype was not associated with either the crypt base or
top (about 75% of the samples were undetermined with FDR > 0.2). Notably, 59% (n = 59)
of the transit-amplifying–subtype tumor samples had a crypt-top signature with low
expression of the Wnt signaling targets LGR5 and ASCL2 (ref. 18). In contrast, the
remaining transit-amplifying–subtype tumors were significantly associated with the crypt
base (Fig. 2a) and showed high mRNA expression of the stem and progenitor markers LGR5
and ASCL2 (Supplementary Fig. 6c). This observation suggests that the transit-amplifying
subtype can be further subdivided.
The colon-crypt base is composed predominantly of stem and progenitor cells that are
known to have high Wnt activity28, and we identified several canonical Wnt gene targets as
components of our stem-like–subtype signature (Supplementary Table 1b). The majority of
the stem-like–subtype tumors from the core CRC data set were associated with high Wnt
activity signature28, as observed in the colon crypt top or base gene signature comparison,
whereas the enterocyte and goblet-like subtypes were not (Fig. 2a). We tested this
association by performing an in vitro Wnt activity assay (TOP-flash) on subtype-specific
CRC cell lines. We observed that 57% (n = 7) of stem-like–subtype cell lines showed high
Wnt activity (above the median TOP-flash signal), as compared to 17% (n = 6) among cell
lines from the other subtypes (Fig. 2b). We further tested this observation by performing
qRT-PCR and immunofluorescence assays on a panel of CRC cell lines using known CRC
markers of differentiation, Wnt signaling or stemness28. This analysis confirmed that the
stem-like subtype was the least differentiated and had the highest expression of Wnt
signaling and stem cell markers. The goblet-like subtype, in contrast, had a well-
differentiated gene expression pattern with comparatively low expression of the stem cell
and Wnt markers (Fig. 2c–f and Supplementary Fig. 2). These results provided further
evidence that the stem-like subtype indeed has a stem or progenitor cell phenotype, whereas
the goblet-like and enterocyte subtypes have a more differentiated phenotype.
The epidermal growth factor receptor (EGFR)-specific monoclonal antibody cetuximab,
which is a mainstay of treatment for metastatic CRC with wild-type KRAS29,30, has failed
to show significant benefit in the adjuvant setting, irrespective of KRAS genotype31. We
correlated subtypes with cetuximab response using a CRC liver metastases microarray
(Khambata-Ford) data set32 annotated with therapeutic responses to cetuximab in 80
patients. NMF consensus clustering with the CRCassigner-786 genes showed that three of
our five subtypes were present in this collection of 80 CRC samples (Fig. 3a and
Supplementary Fig. 7a). We identified a subgroup of samples (n = 26) (termed ‘unknown’)
with a gene expression profile that was highly similar to that of normal liver (Fig. 3a and
Supplementary Table 4a). These samples were not analyzed further. Within the remaining
metastatic CRCs, only 23% (out of 22 samples with known cetuximab response) from the
goblet-like and stem-like subtypes responded to cetuximab. However, 54% (n = 26) of
patients with transit-amplifying–subtype cancer benefitted from cetuximab, whereas the
other 46% of patients had progressive disease. In this case, complete response, partial
response and stable disease were considered as beneficial. These data suggest that the
transit-amplifying subtype designation includes two populations that differ in cetuximab
sensitivity (Fig. 3a).
We explored this segregation in responsiveness by assessing cell proliferation and colony-
forming potential in cultured CRC cell lines representing different subtypes and then
analyzing their growth as xenograft tumors, with and without cetuximab treatment. We
found that a subset of transit-amplifying–subtype cell lines was selectively sensitive to
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treatment (Fig. 3b–g and Supplementary Fig. 7b,c). Specifically, the proliferation of two
transit-amplifying–subtype cell lines (NCI-H508 and SW1116) was significantly impaired
by cetuximab both in vitro and in xenograft tumors, compared to vehicle controls (Fig. 3b–g
and Supplementary Fig. 7b,c). Notably, tumors from the NCI-H508 cell line had not
recurred 45 d after the conclusion of treatment. In contrast, two other transit-amplifying cell
lines showed resistance to cetuximab in vitro (LS1034 and SW948), and both showed
progressive growth as xenograft tumors during treatment with cetuximab (Fig. 3b–g). The
clinical and experimental data collectively support the division of the transit-amplifying–
subtype tumors and cell lines into two sub-subtypes: cetuximab-sensitive transit-amplifying
(CS-TA) and cetuximab-resistant transit-amplifying (CR-TA). This delineation increases the
number of CRC subtypes to six.
We next performed SAM-based differential gene expression analysis on the transit-
amplifying subtype tumors from the Khambata-Ford data set32 (transit-amplifying signature;
FDR = 0.1). This revealed that CS-TA tumors expressed significantly higher levels of the
EGFR ligands epiregulin (EREG) and amphiregulin (AREG), which are known to be
positive predictors of cetuximab response32, as compared to CR-TA tumors (Fig. 3h and
Supplementary Fig. 7d). In contrast, filamin A (FLNA), which regulates the expression and
signaling of the cMET receptor33, was overexpressed in CR-TA compared to CS-TA (Fig.
3h and Supplementary Fig. 7e). This correlation was further confirmed using receiver
operating curve analysis (Supplementary Fig. 7f,g). High FLNA expression was
significantly (P = 0.001; log-rank test; n = 26, Fig. 3i) associated with shorter progression-
free survival only within the transit-amplifying–subtype tumors. However, FLNA
expression did not show prognostic differences when samples from all the subtypes were
included or when all samples were segregated by KRAS status (Supplementary Fig. 7h–k).
Our observation of elevated FLNA expression in CR-TA tumors then led us to examine the
effects on proliferation of pharmacologically inhibiting cMET using the selective small-
molecule inhibitor PFA-665752 in a panel of transit-amplifying cell lines. We found that
CR-TA cell lines were more sensitive to cMET inhibition than CS-TA cell lines (Fig. 3j).
Moreover, we found that three transit-amplifying–subtype samples from Supplementary
Figure 2g could be assigned to CR-TA or CS-TA sub-subtypes (Supplementary Fig. 7l,m)
using a qRT-PCR assay for FLNA (one of the seven genes of CRCassigner-7 signature)
expression. We did not find a significant association between the transit-amplifying subtype
and KRAS mutation status (P = 0.1; chi-square test; Supplementary Results and Discussion
Fig. 3h and Supplementary Fig. 7n–q). Collectively, these results suggest that screening first
for the transit-amplifying subtype with CFTR expression followed by FLNA expression
using qRT-PCR assays (Supplementary Fig. 7l,m) to subdivide the transit-amplifying
subtype into two sub-subtypes could provide an effective means to predict sensitivity to
either cetuximab (low FLNA) or to a cMET inhibitor (high FLNA) in patients with
metastatic, transit-amplifying cancer.
We next examined the possibility that the subtypes might show differential responses to a
chemotherapy regimen deployed in first-line treatment of patients with metastatic CRC
(FOLFIRI, a combination of irinotecan, 5-fluorouracil, and leukovorin)1. This evaluation
was performed by NMF consensus clustering using a gene expression profile data set (Del
Rio data set) of primary CRC samples from patients with metastatic disease with matched
FOLFIRI response data34. We found that 71% of stem-like–subtype tumors (n = 7) in this
data set were associated with clinical benefit to FOLFIRI treatment, whereas only 29% (n =
14) of tumors from the other subtypes were associated with the treatment benefit (Fig. 4a
and Supplementary Fig. 8a–c). We further tested this association by showing that stem-like
samples (100%, n = 18) were significantly (FDR < 0.2) associated with the FOLFIRI
response signature35 in the patients with meta-static disease (Fig. 4b) in the Khambata-Ford
data set32, using the NTP algorithm23.
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Similarly, the FOLFIRI response signature35 was significantly (FDR < 0.2) associated with
100% (n = 74) of the stem-like– and 75% (n = 53) of the inflammatory-subtype samples, as
compared to only 14% (n = 56) of the transit-amplifying–, 39% (n = 33) of the goblet-like–
and 38% (n = 40) of the enterocyte–subtype tumors in the core CRC data sets (comprised of
all Dukes’ stage samples; Fig. 4c and Supplementary Fig. 8d–f) as assessed using the NTP
algorithm. We experimentally assessed the association of the stem-like CRC subtype with
sensitivity to FOLFIRI in a panel of eight CRC cell lines representing different
transcriptional subtypes. We treated these cell lines with 5-fluorouracil (5-FU) plus
irinotecan (the two chemotherapy components of FOLFIRI). Three of the four most
sensitive cell lines were of the stem-like subtype (Fig. 4d). These results are consistent with
the data presented in Figure 1e and Supplementary Figure 5a–d, demonstrating that patients
with stem-like tumors have improved DFS when treated with chemotherapy or
chemoradiotherapy in the adjuvant setting. This finding is also consistent with data from
poor-prognosis subtypes identified in other cancer types, such as basal and claudin-low
breast cancer36 and quasi-mesenchymal pancreatic ductal adenocarcinoma5, which are
comparatively more responsive to chemotherapy than other subtypes.
In summary, we document the existence of six subtypes of CRC based on the combined
analysis of gene expression profiles and differential response to cetuximab. These subtypes
are phenotypically distinct in their DFS (Fig. 5a) and vary in degree of response to
cetuximab and standard-of-care chemotherapy. We also have shown that these CRC
subtypes are associated with distinctive anatomical regions of the colon crypts (phenotype)
and with location-dependent differentiation states and Wnt signaling activity (Fig. 5b). We
identified candidate biomarkers that might be developed into clinical qRT-PCR or
immunohistochemical assays to classify CRC tumors into one of six subtypes (Fig. 5c) as a
guide to assignment of subtype-specific therapeutic agents (Fig. 5d). With regard to first-line
chemotherapy, we infer that particular subtypes might show beneficial responses to
FOLFIRI in either adjuvant or metastatic settings (Fig. 5d), whereas in unselected CRC this
treatment did not improve survival in the adjuvant setting37 Our analyses suggest that stem-
like–subtype tumors, both in the adjuvant and metastatic settings, as well as inflammatory-
subtype tumors in the adjuvant setting, may best be treated with FOLFIRI. Additionally, the
transit-amplifying sub-subtypes and the goblet-like subtype will probably not respond to
FOLFIRI in the adjuvant setting. Watchful surveillance might spare patients with these
forms of disease from the harmful side effects of debilitating and ineffective FOLFIRI
treatment. Moreover, and in contrast to the adjuvant setting, the CS-TA or CR-TA subtype
might be effectively treated with cetuximab or a cMET inhibitor, respectively, in the
metastatic setting (Fig. 5d). These associations warrant further retrospective and prospective
validation. Lastly, we demonstrated that subtype-specific CRC cell lines and xenograft
tumors can serve as surrogates for assessing subtype-specific treatment responses.
Recognition of these subtypes may prove applicable to the assessment of new
investigational drugs in preclinical trials. The outcomes could in turn guide ‘personalized’
therapeutic trial designs that target subtype-selective sensitivities in those patients with CRC
who are most likely to see clinical benefit, much as is becoming standard of care in non–
small-cell lung cancer38.
ONLINE METHODS
Combining different microarray data sets
Microarray data sets from different published studies were screened separately for variable
genes using s.d. cut off greater than 0.8. The screened data sets were column (sample)
normalized to N(0,1) and row (gene) normalized and then merged using Java-based
distance-weighted discrimination14. Finally, the rows were median centered before further
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downstream analysis, as described5. Additional methodological details can be found in the
Supplementary Methods and Supplementary Results and Discussion.
NMF, SAM and PAM analysis
The stable subtypes were identified using consensus clustering-based NMF11 followed by
SAM16 (using classes defined by NMF analysis) and PAM17 (using significant genes
defined by SAM) analysis to identify gene signature specific to each of the subtypes with
modified methods described for glioblastoma classification2. Additional methodological
details can be found in the Supplementary Methods and Supplementary Results and
Discussion.
Drug response in cell lines using proliferation assay
Cells were added (5 × 103) into 96-well plates on day 0 and treated with cetuximab (Merck
Serono, Geneva, Switzerland), cMET inhibitor (PHA-665752, Santa Cruz Biotechnology,
Inc., Santa Cruz, CA), a combination of 5-FU (Sigma-Aldrich, Buchs SG, Switzerland) and
irinotecan (Pfizer AG, Zurich, Switzerland) or vehicle control (medium alone or DMSO) in
the presence of fetal bovine serum on day 1. Proliferation was monitored using CellTiter-
Glo assay kit according to the manufacturer’s instructions (Promega, Dubendorf,
Switzerland) on day 3 (72 h).
TOP flash assay
The TOP/FOP-flash assay was performed as instructed by the manufacturer (Upstate, USA).
Briefly, colon cancer cell lines were plated into 24-well dishes in biological triplicate at
10,000 cells/well in full growth medium (RPMI + 10% FBS). The next day, the medium was
changed to that containing 3 µL of polyethylenimine (stock, 1 mg mL−1), TOP or FOP-flash
DNA (0.25 µg/well) and a plasmid encoding constitutive expression of Renilla luciferase (to
normalize for transfection efficiency). Two days later, the cells were assayed. Samples were
prepared in biological triplicate (n = 3) and the experiment was repeated twice.
Additional methods
Detailed methodology is described in the Supplementary Methods.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
Classification of colorectal tumors and cell lines into subtypes. (a,b) Heatmaps showing
CRC subtypes in tumors (from two merged core data sets: GSE13294 and GSE14333)
defined by CRCassigner-786 (a) and CRCassigner-30 gene signatures (b). (c)
Immunohistochemistry assays of patient CRC samples using candidate CRC subtype-
specific markers (four from the CRCassigner-7) to assign subtypes. For
immunohistochemistry, each subtype-specific marker was scored +, ++ or +++ for weak,
moderate or strong intensity of staining, respectively; see Supplementary Methods and
Supplementary Table 1d for more information. Scale bar represents 100 µm. (d) Heatmap
showing CRC tumor subtypes from the core tumor data sets described in a and b merged
with cancer cell line data19,20. (e) Differential DFS amongst the CRC subtypes from
untreated patients from the GSE14333 data set plotted as Kaplan-Meier survival curves. (f)
Heatmap depicting known MSI or MSS status for each of the colorectal tumor subtype
samples from the data set GSE13294. CFTR, cystic fibrosis transmembrane conductance
regulator; MUC2, mucin 2; TA, transit amplifying; TFF3, trefoil factor 3; ZEB1, zing finger
E-box–binding homeobox-1.
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Figure 2.
Cellular phenotype and Wnt signaling in the CRC subtypes. (a) Heatmap showing
association of colon-crypt location (top or base) and Wnt activity in the patient colorectal
tumors from the core data sets revealed by applying specific signatures27,28 using the NTP
algorithm. In these analyses, statistics include only those samples that were predicted with
FDR < 0.2 (see Supplementary Results and Discussion for statistics from all samples
including those with FDR > 0.2). (b) TOP-flash assay depicting Wnt activity in CRC cell
lines. (c–e) qRT-PCR analysis depicting the average expression of Wnt signaling pathway
(c), stem cell (d) and differentiation-specific (e) markers in a set of CRC subtype-
representative cancer cell lines (HT29 and LS174T for goblet-like; LS1034, NCI-H508 and
SW948 for transit-amplifying; and SW48, HCT8 and SW620 for the stem-like subtype). The
qRT-PCR data is plotted relative to the housekeeping gene RPL13A. Error bars represent
the s.d. of technical replicates from a representative experiment. (f) Immunostaining
analyses for the differentiation markers KRT20 are presented in red, and nuclei are
counterstained with DAPI (blue). HCT116 and COLO320 belong to the stem-like, SW1417
and SW948 belong to transit-amplifying, and HT29 and LS174T belong to the goblet-like
subtypes. Scale bar represents 15 µm.
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Figure 3.
Differential sensitivity among CRC subtypes to cetuximab. (a) Heatmap showing individual
responses of patients with metastatic CRC (Khambata-Ford data set32) to cetuximab
treatment and their association with subtypes. (b) Cetuximab response in CRC subtype–
specific cell lines is plotted as percentage of proliferation of treated cells (cetuximab, 62.5
µg ml−1) normalized to vehicle-treated control. (c) Cetuximab response in transit-amplifying
sub-subtype specific cell lines are plotted as percentage colony formation of treated cells
(cetuximab, 15.6 µg ml−1) normalized to vehicle-treated cells. (d–g) Cetuximab response in
transit-amplifying sub-subtype–specific xenograft tumors using the CS-TA cell lines NCI-
H508 (d) and SW1116 (e) and the CR-TA cell lines LS1034 (f) and SW948 (g). (h)
Heatmap depicting differential gene expression patterns and the KRAS mutation status
between CR-TA and CS-TA subtypes (Khambata-Ford data set). (i) Kaplan-Meier curve of
differential DFS based on FLNA expression in transit-amplifying subtype samples
(Khambata-Ford data set). The expression of FLNA was median-centered across all the 80
samples that belong to different subtypes; those above median were considered as ‘FLNA
high’, and those below the median were considered as ‘FLNA low’. (j) Differential response
to the cMET inhibitor PHA-665752 (625 nM) in CR-TA and CS-TA subtype-specific cell
lines, plotted relative to vehicle-treated cells. Error bars represent the s.d. of technical
replicates (triplicates in b,c and j, where as the sample sizes are indicated for d–g in the
figure) from a representative experiment. *P < 0.05.
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Figure 4.
Specific response to chemotherapy in CRC subtypes. (a) Heatmap showing individual
responses of patients with primary CRC (Del Rio data set34, n = 21) to FOLFIRI treatment
and their association with subtypes. The subtypes in the Del Rio data set were identified
after merging the data set with the core CRC data sets (Supplementary Fig. 8c). Complete
and partial responses and stable disease were considered as beneficial response, whereas
progressive disease was deemed as no response. (b,c) Heatmaps showing association of
individual patient CRC responses in the Khambata-Ford data set (metastases) (b) and in the
core data sets (includes samples from all of the Dukes’ stages) (c) to FOLFIRI by applying
published FOLFIRI response signatures35 using the NTP algorithm. In these analyses,
statistics include only those samples that were predicted with FDR < 0.2. (d) CRC subtype–
specific cell line response to FOLFIRI components. Namely, the combination of 5-FU (239
µM) and irinotecan (22.5 µM), plotted as percentage cellular proliferation and normalized to
vehicle-treated cells. Error bars represent the s.d. of technical replicates from a
representative experiment. *P < 0.05. TA, transit amplifying.
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Figure 5.
Summary, including clinically deployable markers and potential subtype-guided therapies
for CRC. (a) Salient characteristics of the six CRC subtypes. Int, intermediate DFS; Either,
either crypt top or base; NA, no clear association. (b) CRC subtype phenotypes correlated
with colon-crypt location and Wnt signaling. (c) Summary of subtype-specific candidate
biomarkers (CRCassigner-7) that were tested using qRT-PCR and immunohistochemistry
(IHC), and (d) subtype guided therapeutic strategies suggested by the association studies.
ZEB1 was not useful for qRT-PCR because ZEB1 is expressed both by fibroblast and tumor
cells. The expression of ZEB1 specifically in tumor cells was evaluated using
immunohistochemistry as in Figure 1c. TBD, to be determined.
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